Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details
- May 2002 (Revised December 2003)
- Teaching Note
Medicines Company, The TN
Teaching Note for (9-502-006). View Details
- August 2001 (Revised March 2008)
- Case
Helios Health (A)
By: Regina E. Herzlinger and Alfred Martin
Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details
Keywords: Entrepreneurship; Price; Health Care and Treatment; Information Publishing; Innovation and Invention; Product Marketing; Demand and Consumers; Health Industry; Health Industry
Herzlinger, Regina E., and Alfred Martin. "Helios Health (A)." Harvard Business School Case 302-022, August 2001. (Revised March 2008.)
- March 1995 (Revised January 1996)
- Teaching Note
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN
By: David J. Collis
Teaching Note for (9-795-040). View Details
Collis, David J. "Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN." Harvard Business School Teaching Note 795-107, March 1995. (Revised January 1996.)
- 2007
- Chapter
Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business
By: Rohit Deshpandé and Zoe Chance
Keywords: Health Disorders; Poverty; Product Marketing; Customers; Pharmaceutical Industry; Pharmaceutical Industry
Deshpandé, Rohit, and Zoe Chance. "Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business." In Business Solutions for the Global Poor: Creating Social and Economic Value, edited by V. Kasturi Rangan, John A. Quelch, Gustavo Herrero, and Brooke Barton. John Wiley & Sons, 2007.
- September 1990 (Revised March 1991)
- Supplement
RU 486 (B)
Describes how Roussel UCLAF resolved the dilemma. Intended for use as an in-class handout. View Details
Badaracco, Joseph L., Jr. "RU 486 (B)." Harvard Business School Supplement 391-051, September 1990. (Revised March 1991.)
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that... View Details
- 17 Jun 2002
- Research & Ideas
Entrepreneurship in Asia and Foreign Direct Investment
complicated organizational know-how, such as the pharmaceutical and electronics industries.) "The FDI that I'm looking at also has gone into industries in which the local entrepreneurs in these... View Details
Keywords: by Martha Lagace
- 08 Jul 2021
- Blog Post
Managing Sustainable Advantage with Key ESG Co-Founders, Anne-Marie Schoonbeek and Heleen van Poecke
internship and then later back to McKinsey after graduation, where she focused on both large-cap and startups in the pharmaceuticals and biotech space. “For me, this was a way of making an impact,” said Schoonbeek. van Poecke began her... View Details
- 22 Apr 2014
- First Look
First Look: April 22
occurred in the pharmaceutical industry over the past two decades. Since 1989, a number of major pharmaceutical companies (Merck, Novartis, Pfizer, etc.) have chosen to locate... View Details
Keywords: Sean Silverthorne
- April 2024 (Revised November 2024)
- Case
Moderna: Pioneering a People Platform to Accelerate Science Innovation
By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States
Sandino, Tatiana, Emil Dy, and Samuel Grad. "Moderna: Pioneering a People Platform to Accelerate Science Innovation." Harvard Business School Case 124-091, April 2024. (Revised November 2024.)
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details